Literature DB >> 21785823

Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulation.

Hideki Marushima1, Shun-Ichi Shibata, Tadashi Asakura, Tomokazu Matsuura, Haruka Maehashi, Yuji Ishii, Homare Eda, Katsuhiko Aoki, Yasushi Iida, Toshiaki Morikawa, Kiyoshi Ohkawa.   

Abstract

In vitro tumor growth in a three-dimensional (3D) architecture has been demonstrated to play an important role in biology not only for developmental organogenesis and carcinogenesis, but also for analyses on reconstitution and maintenance in a variety of biological environments surrounding the cells. In addition to providing architectural similarity to living organisms, 3D culture with a radial flow bioreactor (RFB) can also closely mimic the living hypoxic microenvironment under which specific organogenesis or carcinogenesis occurs. The findings of the present study under the RFB culture conditions show that cancer cells underwent a shift from aerobic to hypoxic energy metabolism, in addition to protein expression to maintain the 3D structure. In RFB-cultured cells, protein stability of hypoxia-inducible factor 1 (HIF1) α, a subunit of HIF1, was increased without upregulation of its mRNA. Under these conditions, PHD2, HIF-prolyl-4-hydroxy-lase 2 and a HIF1 downstream enzyme, were stabilized without affecting the mRNA levels via downregulation of FK506-binding protein 8. PHD2 accumulation, which occurred concomitant with HIF1 stabilization, may have compensated for the lack of oxygen under hypoxic conditions to regulate the HIF levels. 3D-culture-induced overexpression of carbonic anhydrase (another representative HIF downstream enzyme) was found to occur independently of cell density in RFB--cultured cells, suggesting that the RFB provided an adequately hypoxic microenvironment for the cultured cells. From these results, it was hypothesized that the key factors are regulatory molecules, which stabilize and degrade HIF molecules, thereby activating the HIF1 pathway under a hypoxic milieu.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785823     DOI: 10.3892/ijo.2011.1142

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.

Authors:  Peter C Hart; Hilary A Kenny; Niklas Grassl; Karen M Watters; Lacey M Litchfield; Fabian Coscia; Ivana Blaženović; Lisa Ploetzky; Oliver Fiehn; Matthias Mann; Ernst Lengyel; Iris L Romero
Journal:  Cell Rep       Date:  2019-12-17       Impact factor: 9.423

2.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

3.  Three-dimensional cell culture (3DCC) improves secretion of signaling molecules of mesenchymal stem cells (MSCs).

Authors:  Moyassar Basil Hadi Al-Shaibani
Journal:  Biotechnol Lett       Date:  2022-01-09       Impact factor: 2.461

4.  3D-bioprinted all-inclusive bioanalytical platforms for cell studies.

Authors:  Roya Mazrouei; Vanessa Velasco; Rahim Esfandyarpour
Journal:  Sci Rep       Date:  2020-09-04       Impact factor: 4.379

Review 5.  Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models.

Authors:  Jiyun Kim; Kandice Tanner
Journal:  Front Oncol       Date:  2015-07-29       Impact factor: 6.244

6.  3D matrix-based cell cultures: Automated analysis of tumor cell survival and proliferation.

Authors:  Iris Eke; Stephanie Hehlgans; Veit Sandfort; Nils Cordes
Journal:  Int J Oncol       Date:  2015-11-04       Impact factor: 5.650

7.  2D and 3D cell cultures - a comparison of different types of cancer cell cultures.

Authors:  Marta Kapałczyńska; Tomasz Kolenda; Weronika Przybyła; Maria Zajączkowska; Anna Teresiak; Violetta Filas; Matthew Ibbs; Renata Bliźniak; Łukasz Łuczewski; Katarzyna Lamperska
Journal:  Arch Med Sci       Date:  2016-11-18       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.